Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation
Open Access
- 1 June 2002
- Vol. 87 (6) , 535-543
- https://doi.org/10.1136/heart.87.6.535
Abstract
Objective: To conduct a meta-analysis of randomised controlled trials to estimate the effectiveness of antiarrhythmic drugs at promoting sinus rhythm in patients with atrial fibrillation. Design: Articles were identified by using a comprehensive search of English language papers indexed in Medline from 1966 to August 2001. For the outcomes of sinus rhythm and death, a random effects model was used to model repeated assessments within a study at different time points. Setting: Emergency departments and ambulatory clinics. Patients: Patients with atrial fibrillation. Interventions: Antiarrhythmic agents grouped according to their Vaughan-Williams class. Main outcome measures: Sinus rhythm and mortality. Results: 91 articles met a priori criteria for inclusion in the analysis. Median duration of follow up was one day (range 0.04–1096, mean (SD) 46 (136) days). The median proportion of patients in sinus rhythm at follow up was 55% (range 0–100%) and 32% (range 0–90%) receiving active treatment and placebo, respectively. Median survival was 99% (range 55–100%) and 99% (range 55–100%). Compared with placebo, the following drug classes were associated with increased sinus rhythm at follow up: IA (treatment difference 21.5%, 95% confidence interval (CI) 16.3% to 26.8%); IC (treatment difference 33.1%, 95% CI 23.3% to 42.9%); and III (treatment difference 17.4%, 95% CI 11.5% to 23.3%). Class IC drugs were associated with increased sinus rhythm at follow up compared with class IV drugs (treatment difference 43.2%, 95% CI 11.5% to 75.0%). There was no significant difference in mortality between any drug classes. Conclusions: Class IA, IC, and III drugs are associated with increased sinus rhythm at follow up compared with placebo. It is unclear whether any antiarrhythmic drug class is associated with increased or decreased mortality.Keywords
This publication has 119 references indexed in Scilit:
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trialAmerican Heart Journal, 1999
- Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgeryInternational Journal of Cardiology, 1997
- Effectiveness of Verapamil-Quinidine Versus Digoxin-Quinidine in the Emergency Department Treatment of Paroxysmal Atrial FibrillationAnnals of Emergency Medicine, 1997
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythmInternational Journal of Cardiology, 1994
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Meta-Analyses of Randomized Controlled TrialsNew England Journal of Medicine, 1987
- Diltiazem, Verapamil, and Quinidine in Patients With Chronic Atrial FibrillationThe Journal of Clinical Pharmacology, 1985